Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Product R cleared for Israeli phase I study in leukemia and lymphoma

June 14, 2002

Pharmexa updates AutoVac HER-2 DNA pharmaccine trial progress

June 13, 2002

Medarex and IDM partner to develop Cell Drugs in combination with MDX-010

June 13, 2002

KW-2871 enters malignant melanoma study

June 13, 2002

GVAX cancer vaccines highlighted at the ASGT meeting

June 12, 2002

ING-1 suitable for further evaluation according to initial human study

June 7, 2002

Promising phase I results with ISF-154 lead to initiation of phase II trial in CLL

June 7, 2002

Virulizin granted fast track designation in pancreatic cancer

June 6, 2002

Weekly administration of WX-G250 is safe and effective against renal cell carcinoma

June 5, 2002

MDX-010 induces tumor reductions in phase I trials in metastatic melanoma and prostate cancer

June 5, 2002

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...